Panitumumab vs. Bevacizumab Added to Standard First-Line Chemotherapy

For left-sided, RAS wild-type advanced colorectal cancers, standard care includes first-line chemotherapy combined with either anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) therapy. Retrospective analyses of clinical trials suggest a survival benefit for first-line use of EGFR-targeted agents over the anti-VEGF antibody bevacizumab.

Investigators now report results from the PARADIGM trial from Japan, an industry-sponsored, multicenter, open-label, randomized phase 3 trial in patients with RAS wild-type metastatic colorectal cancer. A total of 802 patients (604 with left-sided primary tumors) were treated with modified fluorouracil, l-leucovorin, and oxaliplatin (mFOLFOX6) plus either the anti-…